How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
the End-To-End Vaccine Supply Chain Market
- By Supply Chain Stage: Vaccine Manufacturing, Cold Chain Logistics, Storage and Warehousing, Distribution and Transportation, Inventory Management
- By Vaccine Type: mRNA Vaccines, Viral Vector Vaccines, Protein Subunit Vaccines, Inactivated Vaccines, Live Attenuated Vaccines
- By Cold Chain Equipment: Refrigerated Containers, Temperature Monitoring Devices, Cold Boxes and Carriers, Ultra-Low Temperature Freezers, Dry Ice Packaging
- By End User: Hospitals and Clinics, Pharmacies, Government Immunization Programs, Private Healthcare Providers, Research Institutions
- By Service Provider: Third-Party Logistics (3PL) Providers, Cold Chain Technology Providers, Packaging Solution Providers, Inventory Management Software Providers, Consulting and Compliance Services
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Vaccine Manufacturing leads By Supply Chain Stage at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 312 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 18 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the the End-To-End Vaccine Supply Chain Market report
A complete, evidence-based study - 12 chapters and 131 sections covering market size, segmentation across 5 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Supply Chain Stage 5
Vaccine Type 5
Cold Chain Equipment 5
End User 5
Service Provider 5
Companies profiled
Pfizer Inc.
Moderna Inc.
Johnson & Johnson
AstraZeneca plc
GlaxoSmithKline plc
Merck & Co. Inc.
Sanofi S.A.
Novartis International AG
Thermo Fisher Scientific Inc.
Catalent Inc.
Lonza Group AG
Becton
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AstraZeneca plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GlaxoSmithKline plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Novartis International AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Thermo Fisher Scientific Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Catalent Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Lonza Group AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →COVAX Facility (Gavi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →WHO
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →CEPI partnership)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →UPS Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →DHL Supply Chain
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$9,844M by 2033 · 10.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Vaccine Manufacturing39.4
- Cold Chain Logistics16.8
- Storage and Warehousing11.5
- Distribution and Transportation14.8
- Inventory Management17.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,436M → $3,187M · 10.5%
Europe$1,001M → $2,065M · 9.5%
Asia Pacific$913.8M → $2,028M · 10.5%
Latin America$565.7M → $1,390M · 11.9%
Middle East and Africa$435.2M → $1,040M · 11.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.692026
10.712027
10.722028
10.722029
10.742030
10.752031
10.772032
10.782033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.12.3
- Moderna Inc.23.7
- Johnson & Johnson8.7
- AstraZeneca plc11.2
- GlaxoSmithKline plc10.2
- Merck & Co. Inc.5.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Supply Chain Stage16.4%
Vaccine Type20.1%
Cold Chain Equipment22.4%
End User19.2%
Service Provider21.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe21.3
- Asia Pacific20.9
- Latin America14.3
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 98 | 81 | 89 | 82 | 77 | 86 | 86 |
| Moderna Inc. | 91 | 74 | 84 | 83 | 73 | 77 | 80 |
| Johnson & Johnson | 88 | 65 | 74 | 78 | 84 | 63 | 75 |
| AstraZeneca plc | 82 | 78 | 66 | 75 | 79 | 57 | 73 |
| GlaxoSmithKline plc | 59 | 52 | 62 | 61 | 75 | 62 | 62 |
| Merck & Co. Inc. | 50 | 53 | 54 | 47 | 55 | 64 | 54 |
| Sanofi S.A. | 40 | 49 | 54 | 54 | 42 | 55 | 49 |
| Novartis International AG | 37 | 41 | 46 | 44 | 38 | 46 | 42 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Moderna Inc.
- Johnson & Johnson
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Moderna Inc. | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Johnson & Johnson | ✓ | − | ◐ | ✓ | ◐ | ◐ |
| AstraZeneca plc | ◐ | ✓ | ◐ | ◐ | ◐ | − |
| GlaxoSmithKline plc | − | − | ◐ | ◐ | ◐ | ◐ |
| Merck & Co. Inc. | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| Sanofi S.A. | − | − | − | − | ◐ | ◐ |
| Novartis International AG | − | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.86
2Moderna Inc.80
3Johnson & Johnson75
4AstraZeneca plc73
5GlaxoSmithKline plc62
6Merck & Co. Inc.54
7Sanofi S.A.49
8Novartis International AG42
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Pfizer Inc.Moderna Inc.
Challenger2
Strong scale, closing on the leaders.
Johnson & JohnsonAstraZeneca plc
Contender1
Focused players with pockets of strength.
GlaxoSmithKline plc
Niche3
Specialists in a single segment or region.
Merck & Co. Inc.Sanofi S.A.Novartis International AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Supply Chain Stage in North America, then scale across the End-To-End Vaccine Supply Chain Market — a $391M beachhead inside a $6.05B market.
Beachhead (SOM)$391Mobtainable near-term
Serviceable (SAM)$2.10Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Vaccine Manufacturing
Best fit — highest urgency & budget in Supply Chain Stage.
Economic buyer81 fit
Cold Chain Logistics
Strong fit — clear ROI and a fast path to value.
End user65 fit
Storage and Warehousing
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Supply Chain Stage in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vaccine Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Cold Chain Equipment
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Supply Chain Stage leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win the End-To-End Vaccine Supply Chain Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified21%
Evaluation13%
Closed-won7%
$14.7KCAC
$75KLTV
5.1:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
the End-To-End Vaccine Supply Chain Market is a durable-growth opportunity — $6.51B by 2033, compounding at 9.6%.
TAM · 2025$3.13Btoday
TAM · 2033$6.51Bforecast
CAGR9.6%2027–2033
Cumulative$41.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.51BTotal addressable market
SAM$2.33BServiceable available market
SOM$382MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.6% CAGR
Demand compounds through 2033, outpacing GDP across Supply Chain Stage.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Supply Chain Stage moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.51BLarge & growingTAM by 2033 at 9.6% CAGR
$2.33BServiceable nowreachable with today’s model
$382MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.08BBear6.2% CAGR
$6.51BBase9.6% CAGR
$8.33BBull12.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vaccine Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
the End-To-End Vaccine Supply Chain Market — a $5.30B market by 2033. Plan: grow share from 9.1% to 18.5%.
Market size · 2033$5.30Btotal addressable
Market CAGR3.6%2027–2033
Target share18.5%from 9.1% today
Revenue ambition$980Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 18.5% | On track |
| Revenue | $509M | $980M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 30.5% | 41.5% | On track |
| Customer retention | 88.5% | 96.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Supply Chain Stage
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Vaccine Type capability
A defensible second engine — invest in Vaccine Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Supply Chain Stage share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vaccine Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $130M capacity & capability investment
- Greenlight bolt-on M&A in Vaccine Type
- Authorise North America expansion plan
- Fund R&D program for Supply Chain Stage leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the the End-To-End Vaccine Supply Chain Market conversation — a $10.3B market you can size, segment and defend in minutes.
Market size · 2033$10.3Btotal opportunity
Growth9.5%CAGR to 2033
Addressable buyers1,499+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Supply Chain Stage
Goal Grow share in Supply Chain Stage
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 2 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Pfizer Inc.Moderna Inc.Johnson & JohnsonAstraZeneca plcGlaxoSmithKline plcMerck & Co. Inc.Sanofi S.A.Novartis International AG+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your the End-To-End Vaccine Supply Chain Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
the End-To-End Vaccine Supply Chain Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →The Autism Service Platform Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportTheatre Suction Trolleys Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportTheacrine Market
Market size, share, segmentation and regional forecast.
$638M market · 2025 base year
View reportTHC (Marijuana) Urine Test Kit Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportTHC-Free CBD Oil Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThapsigargin Market
Market size, share, segmentation and regional forecast.
$881M market · 2025 base year
View reportThalomid Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThalassemia Treatment Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThalassemia Detection Kit Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportThalassemia and Complications Drugs Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportTH1L Antibody Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportT Flask for Stem Cell Culture Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.